JP2021531268A - 改変されたFc抗原結合ドメイン構築体に関する組成物および方法 - Google Patents

改変されたFc抗原結合ドメイン構築体に関する組成物および方法 Download PDF

Info

Publication number
JP2021531268A
JP2021531268A JP2021500915A JP2021500915A JP2021531268A JP 2021531268 A JP2021531268 A JP 2021531268A JP 2021500915 A JP2021500915 A JP 2021500915A JP 2021500915 A JP2021500915 A JP 2021500915A JP 2021531268 A JP2021531268 A JP 2021531268A
Authority
JP
Japan
Prior art keywords
domain
polypeptide
monomer
antigen
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021500915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531268A5 (cg-RX-API-DMAC7.html
Inventor
ジョナサン シー. ランシング
ダニエル オルティス
Original Assignee
モメンタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モメンタ ファーマシューティカルズ インコーポレイテッド filed Critical モメンタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2021531268A publication Critical patent/JP2021531268A/ja
Publication of JP2021531268A5 publication Critical patent/JP2021531268A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021500915A 2018-07-11 2019-07-11 改変されたFc抗原結合ドメイン構築体に関する組成物および方法 Withdrawn JP2021531268A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696618P 2018-07-11 2018-07-11
US62/696,618 2018-07-11
PCT/US2019/041406 WO2020014486A1 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs

Publications (2)

Publication Number Publication Date
JP2021531268A true JP2021531268A (ja) 2021-11-18
JP2021531268A5 JP2021531268A5 (cg-RX-API-DMAC7.html) 2022-07-14

Family

ID=69142016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500915A Withdrawn JP2021531268A (ja) 2018-07-11 2019-07-11 改変されたFc抗原結合ドメイン構築体に関する組成物および方法

Country Status (11)

Country Link
US (1) US20220267460A1 (cg-RX-API-DMAC7.html)
EP (1) EP3820519A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021531268A (cg-RX-API-DMAC7.html)
KR (1) KR20210042326A (cg-RX-API-DMAC7.html)
CN (1) CN113164591A (cg-RX-API-DMAC7.html)
AU (1) AU2019302740A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021000392A2 (cg-RX-API-DMAC7.html)
CA (1) CA3106212A1 (cg-RX-API-DMAC7.html)
IL (1) IL279998A (cg-RX-API-DMAC7.html)
MX (1) MX2021000287A (cg-RX-API-DMAC7.html)
WO (1) WO2020014486A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3511340B1 (en) 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210080460A (ko) * 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
EP4426337A1 (en) * 2021-11-05 2024-09-11 Oslo Universitetssykehus HF Iga fc and igg fc tandem protein constructs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137382A1 (en) * 2007-04-30 2008-11-13 Centocor, Inc. Anti-tissue factor antibodies and compositions with enhanced effector function
SI2185589T1 (sl) * 2007-06-01 2016-04-29 University Of Maryland Baltimore Vezavna sredstva za Fc receptor konstantne regije imunoglobulina
WO2013033008A2 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
KR20150058236A (ko) * 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
SG10201913507SA (en) * 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
IL309293A (en) * 2016-05-23 2024-02-01 Momenta Pharmaceuticals Inc Compositions and methods relating to engineered FC constructs
US20200040084A1 (en) * 2017-01-06 2020-02-06 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs

Also Published As

Publication number Publication date
EP3820519A1 (en) 2021-05-19
CN113164591A (zh) 2021-07-23
KR20210042326A (ko) 2021-04-19
AU2019302740A1 (en) 2021-02-18
MX2021000287A (es) 2021-09-08
EP3820519A4 (en) 2022-04-20
WO2020014486A1 (en) 2020-01-16
BR112021000392A2 (pt) 2021-04-06
IL279998A (en) 2021-03-01
US20220267460A1 (en) 2022-08-25
CA3106212A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
US20220267460A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
JP2021532085A (ja) CTLA−4を標的とする改変されたFc抗原結合ドメイン構築体に関する組成物および方法
JP2020514301A (ja) 改変されたFc抗原結合ドメイン構築体に関する組成物および方法
JP2021530498A (ja) CD38を標的とする改変Fc抗原結合ドメイン構築体に関する組成物および方法
JP2021530992A (ja) 改変されたFc抗原結合ドメイン構築体に関する組成物および方法
JP2021530989A (ja) PD−L1を標的とした改変されたFc抗原結合ドメイン構築体に関する組成物および方法
JP2021531756A (ja) CCR4を標的指向する改変Fc抗原結合ドメイン構築体に関する組成物および方法
JP2021531757A (ja) 改変されたFc−抗原結合ドメイン構築体に関する組成物および方法
JP2021531755A (ja) 改変されたFc−抗原結合ドメイン構築物に関する組成物および方法
JP2022548925A (ja) CD38を標的とした改変されたFc抗原結合ドメイン構築物に関する組成物及び方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210416

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210526

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220706

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220907